J Clin Pathol 54:897-910

Neuroblastoma tumour genetics: clinical and biological aspects

  1. N Bown
  1. School of Biochemistry and Genetics, University of Newcastle upon Tyne/Northern Genetics Service, Royal Victoria Infirmary, 19/20 Claremont Place, Newcastle upon Tyne NE2 4AA, UK
  1. Mr Bown Nick.Bown{at}
  • Accepted 12 April 2001


Neuroblastoma tumour cells show complex combinations of acquired genetic aberrations, including ploidy changes, deletions of chromosome arms 1p and 11q, amplification of the MYCN oncogene, and—most frequently—gains of chromosome arm 17q. Despite intensive investigation, the fundamental role of these features in neuroblastoma initiation and progression remains to be understood. Nonetheless, great progress has been made in relating tumour genetic abnormalities to tumour behaviour and to clinical outcome; indeed, neuroblastoma provides a paradigm for the clinical importance of tumour genetic abnormalities. Knowledge of MYCN status is increasingly being used in treatment decisions for individual children, and the clinical value of 1p and 17q data as adjuncts or refinements in risk stratification is under active investigation. Reliable detection of these molecular cytogenetic features should be regarded as mandatory for all new cases at presentation.


    Free sample
    This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
    View free sample issue >>

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    Navigate This Article